Francesco Panzuto

1035 Grottarossa Street
Rome, 00189, Italy

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 147 publications

Correction: A Randomized clinical trial evaluating the impact on survival and quality of life of 177Lutetium[Lu]-edotreotide versus everolimus in patients with neuroendocrine tumors of the lung and thymus: the LEVEL study (GETNE T-2217).

Correction: A Randomized clinical trial evaluating the impact on survival and quality of life of 177Lutetium[Lu]-edotreotide versus everolimus in patients with neuroendocrine tumors of the lung and thymus: the LEVEL study (GETNE T-2217).

Journal: BMC cancer

Published: June 13, 2026

Characteristics, management, and outcomes of patients with VIPoma-A retrospective analysis of the ENETS database.

Characteristics, management, and outcomes of patients with VIPoma-A retrospective analysis of the ENETS database.

Journal: Journal of neuroendocrinology

Published: March 20, 2026

Management Strategies and Outcomes for Type 1 Gastric Neuroendocrine Tumors Measuring More Than 1 cm.

Management Strategies and Outcomes for Type 1 Gastric Neuroendocrine Tumors Measuring More Than 1 cm.

Journal: Clinical and translational gastroenterology

Published: March 19, 2026

Axitinib and Long-Acting Octreotide in Advanced Extrapancreatic Neuroendocrine Tumors: A Randomized, Double-Blind, Placebo-Controlled, Phase III Clinical Trial (AXINET, GETNE 1107).

Axitinib and Long-Acting Octreotide in Advanced Extrapancreatic Neuroendocrine Tumors: A Randomized, Double-Blind, Placebo-Controlled, Phase III Clinical Trial (AXINET, GETNE 1107).

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: February 20, 2026

Endoscopic follow-up in patients with first-degree relatives for gastric cancer: a real-world observational study.

Endoscopic follow-up in patients with first-degree relatives for gastric cancer: a real-world observational study.

Journal: Expert review of gastroenterology & hepatology

Published: December 20, 2025

Primary tumor size as a prognostic factor in duodenal neuroendocrine neoplasms ≤20 mm: a population-based SEER analysis.

Primary tumor size as a prognostic factor in duodenal neuroendocrine neoplasms ≤20 mm: a population-based SEER analysis.

Journal: Endocrine oncology (Bristol, England)

Published: November 26, 2025

Contrast enhanced endoscopic ultrasound and detective flow imaging for characterization of gastric neuroendocrine neoplasms.

Contrast enhanced endoscopic ultrasound and detective flow imaging for characterization of gastric neuroendocrine neoplasms.

Journal: Endoscopy

Published: November 19, 2025

Real-world presentation and outcomes of gastroenteropancreatic neuroendocrine neoplasms in Italy: findings from the nationwide Itanet prospective database.

Real-world presentation and outcomes of gastroenteropancreatic neuroendocrine neoplasms in Italy: findings from the nationwide Itanet prospective database.

Journal: The Lancet regional health. Europe

Published: November 16, 2025

Corrigendum to "The importance of education and training in neuroendocrine neoplasms: challenges and opportunities for multidisciplinary management". [Cancer Treat. Rev. 139 (2025) 102998].

Corrigendum to "The importance of education and training in neuroendocrine neoplasms: challenges and opportunities for multidisciplinary management". [Cancer Treat. Rev. 139 (2025) 102998].

Journal: Cancer treatment reviews

Published: November 01, 2025

Radiomic and Clinical-Pathological Factors Predictive of Postoperative Recurrence in Lung Neuroendocrine Tumors: A Pilot Study.

Radiomic and Clinical-Pathological Factors Predictive of Postoperative Recurrence in Lung Neuroendocrine Tumors: A Pilot Study.

Journal: Cancers

Published: October 16, 2025

ARTEMIS: a pilot study comparing AI-based and expert therapeutic decisions in simulated clinical cases of neuroendocrine neoplasms.

ARTEMIS: a pilot study comparing AI-based and expert therapeutic decisions in simulated clinical cases of neuroendocrine neoplasms.

Journal: NPJ digital medicine

Published: October 14, 2025

Prognostic value, clinical relevance, and methodological gaps of tumor burden in neuroendocrine tumors (NETs): A systematic review of phase III randomized trials of medical therapies.

Prognostic value, clinical relevance, and methodological gaps of tumor burden in neuroendocrine tumors (NETs): A systematic review of phase III randomized trials of medical therapies.

Journal: Critical reviews in oncology/hematology

Published: September 28, 2025

Showing 1-12 of 147

Last Updated: 09/26/2026